Phase I study with ONCOS-102 for the treatment of solid tumors – an evaluation of clinical response and exploratory analyses of immune markers

Ranki, Tuuli; Pesonen, Sari; Hemminki, Akseli; Partanen, Kaarina; Kairemo, Kalevi; Alanko, Tuomo; Lundin, Johan; Linder, Nina; Turkki, Riku; Ristimäki, Ari; Jäger, Elke; Karbach, Julia; Wahle, Claudia; Kankainen, Matti; Backman, Charlotta; von Euler, Mikael; Haavisto, Elina; Hakonen, Tiina; Heiskanen, Raita; Jaderberg, Magnus; Juhila, Juuso; Priha, Petri; Suoranta, Laura; Vassilev, Lotta; Vuolanto, Antti; Joensuu, Timo

doi:10.1186/s40425-016-0121-5

Table 2 Patient characteristics, prior treatments, response at 3 and 6 months and overall survival

From: Phase I study with ONCOS-102 for the treatment of solid tumors – an evaluation of clinical response and exploratory analyses of immune markers

Patient	WHO score	Cancer type	Previous treatments (other than chemotherapy)	Previous chemotherapy	Response at 3/6 months		Survival (days)
Patient	WHO score	Cancer type	Previous treatments (other than chemotherapy)	Previous chemotherapy	RECIST 1.1	PET	Survival (days)
FI1-01	1	Ovarian carcinoma	Surgery, radiotherapy	Docetaxel + carboplatin, carboplatin, paclitaxel + carboplatin, paclitaxel, gemcitabine, PLD, etoposide, cisplatin, vinorelbine, topotecan, oxaliplatin, docetaxel, epirubicin, irinotecan, gemcitabine hydrochloride, tamoxifen	SD/PD	PMD/SMD	278
FI1-02	0	Metastatic colon carcinoma	Surgery	oxaliplatin, capecitabine, cetuximab + irinotecan + capecitabine	SD/PD	SMD/PMD	382
FI1-04	0	Adenocarcinoma in sigma	-	Oxaliplatin + capecitabine + bevacizumab, Capecitabine + bevacizumab, FolFiri + bevacizumab, xelox	PD/ n/a	PMD/ n/a	124
FI1-06	0	Hepatocellular carcinoma	-	sorafenib tosilate, ramucirumab	PD/ n/a	PMD/ n/a	109
FI1-08	1	Pulmonum adenocarcinoma	Radiotherapy	pemetrexed disodium + cisplatin, erlotinib hydrochloride, docetaxel	PD/ n/a	PMD/ n/a	155
FI1-09	1	Lung mesothelioma	-	pemetrexed + cisplatin, tramadol hydrochloride	PD/ n/a	SMD/ n/a	254
FI1-13	0	Rectal adenocarcinoma	Surgery	Oxaliplatin + capecitabine, bevacizumab, irinotecan + capecitabine, panitumumab	PD/ n/a	PMD/ n/a	290
FI1-14	1	Asbestos related pleural mesothelioma	Radiotherapy	Docetaxel, cisplatin + pemetrexed disodium	SD/PD	PMD/PMD	542
FI1-15	1	Serous endometrial cancer	Surgery, Radiotherapy	PLD, paclitaxel + carboplatin x 2, gemcitabine, topotecan, docetaxel	- ^a	- ^a	90
FI1-17	1	Soft tissue sarcoma	Surgery, Radiotherapy	Ifosfamide + doxorubicin, gemcitabine + docetaxel, letrozole, trabectedin, zoledronic acid, gemcitabine + docetaxel, pazopanib hydrochloride	PD/PD	PMD/PMD	330
FI1-18	1	Breast cancer	Surgery, Radiotherapy	Docetaxel x2, cyclophosphamide + epirubicin + fluorouracil x 2, tamoxifen citrate, letrozole, anastrozole x2, exemestane, bevacizumab, capecitabine, medroxyprogesterone acetate, vinorelbine tartrate, epirubicin, cisplatin + gemcitabine, cyclophosphamide + methotrexate sodium	- ^a	- ^a	63
FI1-19	0	Ovarian cancer	Surgery	Paclitaxel + carboplatin x 2, paclitaxel + cisplatin, docetaxel + cisplatin, topotecan, gemcitabine, etoposide	SD/PD	SMD/PMD	761^b

PLD Pegylated liposomal doxorubicin hydrochloride, FolFri fluorouracil w/folinic acid/irinotecan, SD stable disease, PD progressive disease, SMD stable metabolic disease, PMD progressive metabolic disease
^aPatient died before the imaging at 3 month time-point
^bPatient alive on 16June2015, n/a = patient withdrawn from the trial

Back to article page